在过敏性喘中,MOTS-c通过通过Nrf2通路抑制表皮细胞亡,减轻呼吸道屏障功能障碍
Wenlong Zhang1, Shengpeng Li2, Yanli Zhang2
1Department of Respiratory and Critical Care Medicine, Jiangnan University Medical Center, 68 Zhongshan Road, Wuxi 2140002, Jiangsu Province, PR China; Wuxi School of Medicine, Jiangnan University, 1800 Lihu Avenue, Wuxi 214122, Jiangsu Province, PR China.
International immunopharmacology
|June 5, 2025
概括
补充MOTS-c可以通过增强呼吸道上皮质屏障功能和减少炎症来改善过敏性喘. 这种可以通过Nrf2通路保护肺损伤和线粒体功能障碍.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 过敏性喘 (AA) 涉及慢性呼吸道炎症和支气管上皮质屏障功能受损.
- MOTS-c/核因子红色素2相关因子2 (Nrf2) 途径因其抗炎和保护作用而得到认可.
- 这项研究研究了MOTS-c在过敏性喘中的治疗潜力,重点关注呼吸道上皮质屏障的完整性.
研究的目的:
- 在过敏性喘的背景下,评估MOTS-c对气道上皮质屏障功能的影响.
- 阐明潜在的机制,特别是Nrf2通路的参与.
主要方法:
- 在喘患者和健康对照人群中,使用ELISA量化了血清MOTS-c水平.
- 在C57BL/6和Nrf2-Knockout小鼠中建立了一种过敏喘模型,使用室内灰尘虫 (HDM) 暴露.
- 在体外实验中,使用MOTS-c对BEAS-2B细胞进行治疗,然后进行HDM刺激,以评估表皮屏障和线粒体功能.
主要成果:
- 与健康个体相比,喘患者的血清MOTS-c水平较低.
- 外源MOTS-c的使用在小鼠中减轻了HDM诱导的肺组织损伤,炎症和氧化应激.
- MOTS-c治疗逆转了HDM刺激的支气管上皮细胞中的屏障功能障碍和线粒体损伤,通过Nrf2通路起作用.
结论:
- MOTS-c通过加强气道上皮屏障,显示出对过敏性喘的保护作用.
- MOTS-c的治疗效益通过一个依赖Nrf2的机制来调解,减少炎症和亡.
- MOTS-c作为治疗过敏喘的潜在新型治疗剂具有前景.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
505
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
505
01:20Asthma: Pathogenesis and Management
623
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
623
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
490
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
490
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
479
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
479
01:17Drugs Used in Lower Respiratory Disorders: Overview
635
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
635